Research ExplorerPublicationsInterleukin-17 cytokines: Effectors and targets in psoriasis...

Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment

Standard

Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. / Prinz, Immo; Sandrock, Inga; Mrowietz, Ulrich.

In: J EXP MED, Vol. 217, No. 1, 06.01.2020.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Prinz, I, Sandrock, I & Mrowietz, U 2020, 'Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment', J EXP MED, vol. 217, no. 1. https://doi.org/10.1084/jem.20191397

APA

Prinz, I., Sandrock, I., & Mrowietz, U. (2020). Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. J EXP MED, 217(1). https://doi.org/10.1084/jem.20191397

Vancouver

Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment. J EXP MED. 2020 Jan 6;217(1). https://doi.org/10.1084/jem.20191397

Bibtex

@article{b1bd72c09e7c44d0845bb8ca2f331860,
title = "Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment",
abstract = "The IL-17 cytokine family comprising IL-17A to IL-17F and receptor subunits IL-17RA to IL-17RE represents a genetically ancient intercellular network regulating local tissue homeostasis. Its pivotal role in antifungal defense and its central position in the pathogenesis of inflammatory diseases including psoriasis were discovered only relatively late in the early 2000s. Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.",
keywords = "Animals, Antibodies, Monoclonal/immunology, Arthritis, Psoriatic/immunology, Cytokines/immunology, Humans, Interleukin-17/immunology, Psoriasis/immunology, Receptors, Interleukin-17/immunology",
author = "Immo Prinz and Inga Sandrock and Ulrich Mrowietz",
note = "{\textcopyright} 2019 Prinz et al.",
year = "2020",
month = jan,
day = "6",
doi = "10.1084/jem.20191397",
language = "English",
volume = "217",
journal = "J EXP MED",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment

AU - Prinz, Immo

AU - Sandrock, Inga

AU - Mrowietz, Ulrich

N1 - © 2019 Prinz et al.

PY - 2020/1/6

Y1 - 2020/1/6

N2 - The IL-17 cytokine family comprising IL-17A to IL-17F and receptor subunits IL-17RA to IL-17RE represents a genetically ancient intercellular network regulating local tissue homeostasis. Its pivotal role in antifungal defense and its central position in the pathogenesis of inflammatory diseases including psoriasis were discovered only relatively late in the early 2000s. Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.

AB - The IL-17 cytokine family comprising IL-17A to IL-17F and receptor subunits IL-17RA to IL-17RE represents a genetically ancient intercellular network regulating local tissue homeostasis. Its pivotal role in antifungal defense and its central position in the pathogenesis of inflammatory diseases including psoriasis were discovered only relatively late in the early 2000s. Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.

KW - Animals

KW - Antibodies, Monoclonal/immunology

KW - Arthritis, Psoriatic/immunology

KW - Cytokines/immunology

KW - Humans

KW - Interleukin-17/immunology

KW - Psoriasis/immunology

KW - Receptors, Interleukin-17/immunology

U2 - 10.1084/jem.20191397

DO - 10.1084/jem.20191397

M3 - SCORING: Review article

C2 - 31727784

VL - 217

JO - J EXP MED

JF - J EXP MED

SN - 0022-1007

IS - 1

ER -